Overview Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage Status: Recruiting Trial end date: 2022-06-28 Target enrollment: Participant gender: Summary The study is ongoing to evaluate the efficacy and safety of SHR-1209 in patients with hypercholesterolemia and hyperlipemia. Phase: Phase 3 Details Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.